Verastem FY2025 EPS Estimate Decreased by Cantor Fitzgerald

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Verastem in a research report issued on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the biopharmaceutical company will post earnings of ($3.57) per share for the year, down from their prior forecast of ($3.24). The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem's FY2026 earnings at ($3.69) EPS.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.24).

VSTM has been the topic of a number of other reports. Jefferies Financial Group assumed coverage on shares of Verastem in a research note on Thursday, April 10th. They issued a "buy" rating and a $15.00 price target on the stock. HC Wainwright boosted their target price on Verastem from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Wall Street Zen lowered Verastem from a "hold" rating to a "sell" rating in a research report on Friday, April 18th. Royal Bank Of Canada upgraded Verastem from an "outperform" rating to a "moderate buy" rating and reduced their price target for the company from $16.00 to $12.00 in a report on Wednesday. Finally, Guggenheim boosted their price target on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Monday, March 24th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Verastem presently has an average rating of "Moderate Buy" and an average price target of $13.38.

Verastem Stock Down 3.3%

VSTM stock traded down $0.14 during midday trading on Thursday, reaching $4.16. The company had a trading volume of 3,175,515 shares, compared to its average volume of 1,219,073. The company has a 50 day moving average of $6.68 and a two-hundred day moving average of $5.99. The company has a market capitalization of $228.59 million, a P/E ratio of -1.30 and a beta of 0.85. Verastem has a 1 year low of $2.10 and a 1 year high of $9.10. The company has a current ratio of 3.50, a quick ratio of 3.50 and a debt-to-equity ratio of 2.77.

Insider Activity

In related news, CEO Dan Paterson sold 58,677 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.13, for a total value of $477,044.01. Following the completion of the sale, the chief executive officer now directly owns 461,982 shares in the company, valued at approximately $3,755,913.66. The trade was a 11.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Daniel Calkins sold 11,143 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.13, for a total value of $90,592.59. Following the transaction, the chief financial officer now owns 114,055 shares in the company, valued at approximately $927,267.15. This trade represents a 8.90% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,796 shares of company stock valued at $693,033. Insiders own 2.10% of the company's stock.

Institutional Investors Weigh In On Verastem

Hedge funds and other institutional investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. bought a new stake in Verastem during the 4th quarter valued at approximately $20,400,000. AIGH Capital Management LLC acquired a new position in shares of Verastem during the fourth quarter worth approximately $13,778,000. Octagon Capital Advisors LP bought a new stake in shares of Verastem in the first quarter valued at approximately $10,372,000. Rosalind Advisors Inc. bought a new stake in shares of Verastem in the fourth quarter valued at approximately $4,653,000. Finally, Marshall Wace LLP acquired a new stake in shares of Verastem in the fourth quarter worth $4,103,000. 88.37% of the stock is owned by institutional investors and hedge funds.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.